drugset / Trial / NCT01261000

Tissue Biomarker for Pegvisomant Action

NCT01261000

Completed 8 enrolled Cedars-Sinai Medical Center
NaSingle-groupOpen-labelTreatment

Summary

Acromegaly is a disease of the pituitary gland that involves overproduction of growth hormone. Pegvisomant works by blocking binding of GH to receptors found in tissues throughout the body. Human studies have evaluated pegvisomant action by measuring reduction of IGF-I levels in the blood. However, no studies have evaluated the effects of blocking GH receptors in tissues. In this study, we will study tissue biomarkers for pegvisomant action in GH and IGF-I dependent signaling pathways in colon tissue of patients with acromegaly treated with pegvisomant.

Timeline

Start
2010-11
Primary completion
2013-03
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegvisomant Protein / enzyme biologic

Indications